R-Pharm to conduct clinical study of radotinib for treatment of COVID-19

May 28

R-Pharm JSC has obtained official permission to conduct clinical trial in Russia to evaluate the efficacy and safety of radotinib for treatment of patients with COVID-19.

For last 6 years, IL-YANG PHARM CO., LTD. has been developing antiviral compounds. In 2015, IL-YANG PHARM. CO., LTD submitted a patent application on radotinib as a medicine for treatment of coronavirus infections caused by SARS-CoV and MERS-CoV. In Early 2020, a range of in vitro pharmacological trials was conducted in Korea University College of Medicine in Center for Biosafety (BSL-3 facility.). These studies showed that radotinib significantly inhibits replication of SARS-CoV-2 virus within 48 hours after treatment.

R-Pharm will conduct a multicenter randomized Phase III clinical study to evaluate the efficacy and safety of radotinib for treatment of hospitalized patients with COVID-19 in 11 clinical sites across Russia

“Clinical practice shows that many existing drugs can be successfully used for treatment of infection caused by the new coronavirus. The antiviral effect of radotinib against coronaviruses was already confirmed in preclinical in vitro studies, which showed 80-85% antiviral effect. We believe that radotinib has therapeutic potential and can help patients to recover faster after disease onset”, said Chief Medical Officer of R-Pharm Mikhail Samsonov.

Radotinib

Radotinib (Supect®), developed by IL-YANG PHARM. CO., LTD, is a 2nd generation Bcr-Abl tyrosine kinase inhibitor (TKI) for the treatment of Philadelphia chromosome positive (Ph(+)) chronic myeloid leukemia. Radotinib was developed by IL-YANG PHARM. CO., LTD and approved by the Korean Ministry of Food and Drug Safety (MFDS) in 2012 for long-term treatment of patients with chronic myeloid leukemia after treatment failure with other tyrosine kinase inhibitors. Since October 2015, this drug is approved for the first line therapy in patients with chronic myeloid  leukemia. Safety and efficacy of radotinib were already confirmed in several clinical studies.

About R-Pharm Group

R-Pharm Group introduces comprehensive solutions for the healthcare system and focuses on research, development, manufacturing and commercialization of pharmaceuticals, laboratory equipment and medical devices. R-Pharm's mission is to increase the accessibility of advanced diagnostics, preventative care and therapy methods in Russia and abroad.

More than 3,000 employees of the group in 70 branches and 30 countries of the world do their best to provide as many people as possible with the necessary means to improve and prolong their lives.

IL-YANG PHARM. CO., LTD

IL-YANG PHARM. CO., LTD, is one of the leading Korean pharmaceutical company, established in 1946; This company has dedicated to research and development for 70 years in the area of Oncology, Gastroenterology, Urology, Virology, and Vaccine. After years of dedication to research and development, IL-YANG developed 2 new drugs and an Influenza vaccine.

Other company news

Coronavir is one of the first medicine, both in Russia and globally, directly targeting the virus rather than merely addressing the...
read more...
September 17
Olokizumab is the first Russian original biologic for treatment of rheumatoid arthritis and also the first global direct inhibitor of...
read more...
September 14
The interim analysis of randomized Phase III clinical trial of Coronavir (favipiravir) has been published  in the peer-reviewed scientific...
read more...
August 10